MSD Animal Health gets European Commission marketing nod for INNOVAX-ND-H5 vaccine for chickens
Rahway: MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, has announced that the European Commission has granted the marketing authorization for the INNOVAX-ND-H5 vaccine for chickens. This vaccine is the first centrally registered vaccine in the European Union against the currently circulating avian influenza virus strains of clade 2.3.4.4b, which cause high mortality in poultry. Any use of vaccines for HPAI should be done in conjunction with rigorous biosecurity and surveillance programs and in line with Government regulations.
“We are pleased that the European Commission has approved INNOVAX-ND-H5 vaccine for chickens,” said Maxim Nakhodko, Global Poultry Business Unit Lead, MSD Animal Health. “This vaccine bolsters MSD Animal Health’s avian influenza portfolio, which consists of inactivated vaccines for the H5 and H9 hemagglutinin subtypes and can help reduce the challenges raised by avian influenza and offer an optimized HPAI control system.”
INNOVAX-ND-H5 is a single-dose product administered in ovo or subcutaneously at one day of age to reduce mortality, clinical signs and virus excretion due to infection with highly pathogenic Avian Influenza (HPAI) virus of the H5 type. In addition, the vaccine induces active immunity against Marek’s disease and Newcastle disease and data is available that the vaccine can safely be administered in combination with NOBILIS RISMAVAC, MSD Animal Health’s Rispens strain Marek’s disease vaccine.
INNOVAX-ND-H5 forms part of a holistic Avian influenza solution strategy aiming to clinically protect poultry and minimizing or ideally eliminating avian influenza virus shed over the whole life cycle of the birds. In fact, the 180+ countries of the World Health Organisation for Animals (WOAH) agreed in a 2023 Resolution that “conventional control measures of biosecurity, stamping out and movement restrictions…can be insufficient and unsustainable” and that “vaccination should be considered as a complementary disease control tool.”
Read also: Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint: Merck
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.